NitroMed to Report Financial Results for Second Fiscal Quarter 2008

NitroMed, Inc. (NASDAQ: NTMD), announced today that on Tuesday August 5, 2008 it will release financial results for the Company’s second fiscal quarter ended June 30, 2008. Following the release, NitroMed will host a webcast and conference call to report on second quarter performance and recent activities.   Event:     Q2 2008 NitroMed, Inc. Earnings Call Date: Tuesday, August 5, 2008 Time: 8:00 a.m. Eastern Time Access by Conference Call: Domestic callers:     Dial 800-356-4123 International callers: Dial 617-597-5393 Participant passcode: 32967472 Access by Webcast: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=130535&eventID=1908629 An audio replay of the earnings conference call will be available two hours after the call and through August 12, 2008. The replay can be accessed by dialing 888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 86745157. The webcast will be archived on the Company’s website for an indefinite period of time following the earnings call. About NitroMed, Inc. NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil® (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company’s landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization. For full prescribing information, visit: www.BiDil.com. BiDil is a registered trademark of NitroMed, Inc.